JPWO2021077067A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021077067A5
JPWO2021077067A5 JP2022523023A JP2022523023A JPWO2021077067A5 JP WO2021077067 A5 JPWO2021077067 A5 JP WO2021077067A5 JP 2022523023 A JP2022523023 A JP 2022523023A JP 2022523023 A JP2022523023 A JP 2022523023A JP WO2021077067 A5 JPWO2021077067 A5 JP WO2021077067A5
Authority
JP
Japan
Prior art keywords
lnp
substituted
composition
tissue
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022523023A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022552008A5 (https=
JP7744687B2 (ja
JP2022552008A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/056255 external-priority patent/WO2021077067A1/en
Publication of JP2022552008A publication Critical patent/JP2022552008A/ja
Publication of JPWO2021077067A5 publication Critical patent/JPWO2021077067A5/ja
Publication of JP2022552008A5 publication Critical patent/JP2022552008A5/ja
Priority to JP2025147778A priority Critical patent/JP2025175052A/ja
Application granted granted Critical
Publication of JP7744687B2 publication Critical patent/JP7744687B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022523023A 2019-10-18 2020-10-19 CAR mRNA送達のための脂質ナノ粒子とその製剤 Active JP7744687B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025147778A JP2025175052A (ja) 2019-10-18 2025-09-05 CAR mRNA送達のための脂質ナノ粒子とその製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962916942P 2019-10-18 2019-10-18
US62/916,942 2019-10-18
PCT/US2020/056255 WO2021077067A1 (en) 2019-10-18 2020-10-19 Lipid nanoparticles and formulations thereof for car mrna delivery

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025147778A Division JP2025175052A (ja) 2019-10-18 2025-09-05 CAR mRNA送達のための脂質ナノ粒子とその製剤

Publications (4)

Publication Number Publication Date
JP2022552008A JP2022552008A (ja) 2022-12-14
JPWO2021077067A5 true JPWO2021077067A5 (https=) 2023-10-25
JP2022552008A5 JP2022552008A5 (https=) 2023-10-25
JP7744687B2 JP7744687B2 (ja) 2025-09-26

Family

ID=75538674

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022523023A Active JP7744687B2 (ja) 2019-10-18 2020-10-19 CAR mRNA送達のための脂質ナノ粒子とその製剤
JP2025147778A Pending JP2025175052A (ja) 2019-10-18 2025-09-05 CAR mRNA送達のための脂質ナノ粒子とその製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025147778A Pending JP2025175052A (ja) 2019-10-18 2025-09-05 CAR mRNA送達のための脂質ナノ粒子とその製剤

Country Status (8)

Country Link
US (1) US20220378700A1 (https=)
EP (1) EP4045021A4 (https=)
JP (2) JP7744687B2 (https=)
KR (1) KR20220084366A (https=)
CN (1) CN114828837A (https=)
AU (1) AU2020366519A1 (https=)
CA (1) CA3155075A1 (https=)
WO (1) WO2021077067A1 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL303195A (en) 2020-11-25 2023-07-01 Akagera Medicines Inc Lipid nanoparticles for delivery of nucleic acids and related methods of use
CA3223590A1 (en) * 2021-06-14 2022-12-22 Flagship Pioneering Innovations Vi, Llc Modification of plant messenger packs
WO2023023055A1 (en) 2021-08-16 2023-02-23 Renagade Therapeutics Management Inc. Compositions and methods for optimizing tropism of delivery systems for rna
CN115724806B (zh) * 2021-08-25 2025-07-01 广州谷森制药有限公司 阳离子脂质化合物
CN118317944A (zh) 2021-09-14 2024-07-09 雷纳嘉德医疗管理公司 非环状脂质及其使用方法
TW202328067A (zh) 2021-09-14 2023-07-16 美商雷納嘉德醫療管理公司 環狀脂質及其使用方法
EP4408437A4 (en) * 2021-10-01 2025-08-27 Univ Pennsylvania LIPID NANOPARTICLE (LNP) COMPOSITIONS AND METHODS OF USE THEREOF
EP4426832A1 (en) 2021-11-03 2024-09-11 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Precise genome editing using retrons
WO2023122752A1 (en) 2021-12-23 2023-06-29 Renagade Therapeutics Management Inc. Constrained lipids and methods of use thereof
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2023183300A1 (en) * 2022-03-22 2023-09-28 The Children's Medical Center Corporation Compositions and methods for prevention and treatment of genetic disease
CA3255619A1 (en) 2022-04-07 2023-10-12 Renagade Therapeutics Management Inc. CYCLIC LIPIDS AND LIPID NANOPARTICLES (LPNs) FOR THE SUPPLY OF NUCLEIC ACIDS OR PEPTIDES INTENDED FOR USE IN VACCINATION AGAINST INFECTIOUS AGENTS
EP4519243A4 (en) * 2022-05-04 2026-04-22 Univ Pennsylvania Siloxane-based lipids, lipid nanoparticle compositions comprising them, and their methods of use for targeted administration
EP4531819A2 (en) 2022-05-25 2025-04-09 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
JP2025525569A (ja) 2022-07-18 2025-08-05 レナゲード セラピューティクス マネージメント インコーポレイテッド 遺伝子編集成分、システム、及び使用方法
EP4561537A2 (en) * 2022-07-27 2025-06-04 Trustees Of Tufts College Lipid nanoparticles for immunotherapy
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
EP4680595A2 (en) 2023-03-15 2026-01-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2024192291A1 (en) 2023-03-15 2024-09-19 Renagade Therapeutics Management Inc. Delivery of gene editing systems and methods of use thereof
EP4680728A1 (en) 2023-03-17 2026-01-21 Quell Therapeutics Limited Treg therapy
WO2024206230A1 (en) * 2023-03-24 2024-10-03 Trustees Of Tufts College Tissue targeting lipids and lipid nanoparticles
WO2024220609A1 (en) * 2023-04-18 2024-10-24 The Trustees Of The University Of Pennsylvania Ionizable lipid compounds, lipid nanoparticles (lnps) comprising the same, and methods of use thereof for cell engineering
WO2025007148A1 (en) 2023-06-30 2025-01-02 Orna Therapeutics, Inc. Polymer lipid nanoparticle compositions for delivering circular polynucleotides
KR20260033596A (ko) * 2023-07-06 2026-03-10 이더알엔에이 이뮤노테라피스 엔브이 이온화 가능한 지질
IT202300015003A1 (it) * 2023-07-18 2025-01-18 Univ Degli Studi Di Salerno Composizione e procedimento per la realizzazione di nano-carriers lipidici ed i relativi nano-carriers lipidici di uso biomedico
WO2025038494A1 (en) 2023-08-11 2025-02-20 Tune Therapeutics, Inc. Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation
AU2024335327A1 (en) 2023-09-01 2026-03-26 Renagade Therapeutics Management Inc. Gene editing systems, compositions, and methods for treatment of vexas syndrome
WO2025072623A1 (en) * 2023-09-28 2025-04-03 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting immune cells
WO2025075396A1 (ko) * 2023-10-06 2025-04-10 한국과학기술연구원 타겟 핵산 검출물질이 담지된 지질 나노입자 및 이를 이용한 막융합 기반의 타겟 핵산 검출 방법
WO2025081042A1 (en) 2023-10-12 2025-04-17 Renagade Therapeutics Management Inc. Nickase-retron template-based precision editing system and methods of use
WO2025090525A1 (en) * 2023-10-22 2025-05-01 Tessera Therapeutics, Inc. Lipid nanoparticles for delivery of therapeutic payloads to t cells
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025129333A1 (en) * 2023-12-18 2025-06-26 Nanovation Therapeutics Inc. Lipid nanoparticles having non-polar lipids for nucleic acid delivery to the liver
WO2025144938A1 (en) 2023-12-26 2025-07-03 Emmune, Inc. Systems for nucleic acid transfer
WO2025155753A2 (en) 2024-01-17 2025-07-24 Renagade Therapeutics Management Inc. Improved gene editing system, guides, and methods
WO2025166238A1 (en) 2024-01-31 2025-08-07 Orna Therapeutics, Inc. Fast-shedding polyethylene glycol lipids
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025184476A1 (en) * 2024-02-29 2025-09-04 The Trustees Of The University Of Pennsylvania Cationic degradable lipid compositions, lipid nanoparticles (lnps) comprising same, and methods of use thereof
WO2025252759A1 (en) 2024-06-03 2025-12-11 Bio-Sourcing Transient expression by lipid nanoparticle formulations
WO2026003582A2 (en) 2024-06-27 2026-01-02 Axelyf ehf. Lipids and lipid nanoparticles
WO2026015458A1 (en) * 2024-07-08 2026-01-15 Memorial Sloan-Kettering Cancer Center Cells comprising non-hla restricted t cell receptors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2646630T3 (es) * 2008-11-07 2017-12-14 Massachusetts Institute Of Technology Lipidoides aminoalcohólicos y usos de los mismos
US9126966B2 (en) * 2011-08-31 2015-09-08 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use thereof
US11219634B2 (en) * 2015-01-21 2022-01-11 Genevant Sciences Gmbh Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells
HUE057877T2 (hu) 2015-12-22 2022-06-28 Modernatx Inc Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására
US20190241658A1 (en) * 2016-01-10 2019-08-08 Modernatx, Inc. Therapeutic mRNAs encoding anti CTLA-4 antibodies
JP2019529499A (ja) * 2016-09-30 2019-10-17 ベイラー カレッジ オブ メディスンBaylor College Of Medicine 組織指向性発現を用いた抗体ベースの遺伝子治療
JP2021512090A (ja) * 2018-01-30 2021-05-13 モデルナティーエックス, インコーポレイテッド 免疫細胞に薬剤を送達するための組成物及び方法

Similar Documents

Publication Publication Date Title
JPWO2021077067A5 (https=)
JP2025175052A5 (https=)
JP2026012402A5 (https=)
JPWO2021077066A5 (https=)
US10626393B2 (en) Delivering CRISPR therapeutics with lipid nanoparticles
US20180245074A1 (en) Treating hepatitis b virus infection using crispr
Xu et al. Exploring precision treatments in immune‐mediated inflammatory diseases: Harnessing the infinite potential of nucleic acid delivery
JP2012509258A (ja) 核酸送達系のための分岐カチオン性脂質
JP2012509366A (ja) 核酸送達系のための放出可能ポリマー脂質
JP7592493B2 (ja) 治療用タンパク質の標的細胞に特異的な産生のための、および、標的細胞に関連する疾患、疾病、または障害の処置のための、融合性脂質ナノ粒子、および、融合性脂質ナノ粒子の製造方法と使用方法
EP4667004A1 (en) Lipid composition targeting antigen-presenting cells and use thereof
JP2025541727A (ja) 新規のポリグリセロールコンジュゲート脂質及びそれを含む脂質ナノ粒子組成物
WO2018232330A1 (en) Therapeutic compositions and methods for treating hepatitis b
US20250325490A1 (en) Lipid compound, lipid nanoparticle comprising same and use thereof
CN120835876A (zh) 包括具有支化结构的电离脂质的脂质纳米粒制剂及其用途
JP2000143549A (ja) ポリヌクレオチドを細胞にトランスフェクトさせる治療用組成物の製造におけるマグネシウム(Ma2+)の使用、および遺伝子治療に有用な組成物
WO2023019310A1 (en) Lipid nanoparticle formulations
RU2476204C2 (ru) Носитель лекарственного средства
US20240417738A1 (en) Immunotherapies for the treatment of cancer
JP2005513073A (ja) ポリヌクレオチドを細胞へトランスフェクションするための組成物の製造のためのリゾ脂質の使用
JP2005513073A6 (ja) ポリヌクレオチドを細胞へトランスフェクションするための組成物の製造のためのリゾ脂質の使用
WO2023085440A1 (ja) 難治性ウイルス感染症の治療剤
KR20220026197A (ko) 세포 투과성 핵산 복합체를 유효성분으로 함유하는 류마티스 관절염의 예방 또는 치료용 조성물
JP2002533354A (ja) 安定なポジプレックスの懸濁液の製造法
WO2026020403A1 (en) Ionizable lipid derived from alkyl substituted 1, 4, 7-triazacyclononane or 1, 4, 7, 10-tetraazacyclododecane, compositions and uses thereof